10-Q 1 icui-20240630.htm 10-Q icui-20240630
0000883984ICU MEDICAL INC/DEFALSEDecember 312024Q2http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2023#CostOfRevenuehttp://fasb.org/us-gaap/2023#InterestExpensehttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pure00008839842024-01-012024-06-3000008839842024-07-3100008839842024-06-3000008839842023-12-3100008839842024-04-012024-06-3000008839842023-04-012023-06-3000008839842023-01-012023-06-300000883984icui:CommonStockSharesMember2023-12-310000883984us-gaap:CommonStockMember2023-12-310000883984us-gaap:AdditionalPaidInCapitalMember2023-12-310000883984us-gaap:TreasuryStockCommonMember2023-12-310000883984us-gaap:RetainedEarningsMember2023-12-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000883984icui:CommonStockSharesMember2024-01-012024-03-310000883984us-gaap:CommonStockMember2024-01-012024-03-310000883984us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000883984us-gaap:TreasuryStockCommonMember2024-01-012024-03-3100008839842024-01-012024-03-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000883984us-gaap:RetainedEarningsMember2024-01-012024-03-310000883984icui:CommonStockSharesMember2024-03-310000883984us-gaap:CommonStockMember2024-03-310000883984us-gaap:AdditionalPaidInCapitalMember2024-03-310000883984us-gaap:TreasuryStockCommonMember2024-03-310000883984us-gaap:RetainedEarningsMember2024-03-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100008839842024-03-310000883984icui:CommonStockSharesMember2024-04-012024-06-300000883984us-gaap:CommonStockMember2024-04-012024-06-300000883984us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000883984us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000883984us-gaap:RetainedEarningsMember2024-04-012024-06-300000883984icui:CommonStockSharesMember2024-06-300000883984us-gaap:CommonStockMember2024-06-300000883984us-gaap:AdditionalPaidInCapitalMember2024-06-300000883984us-gaap:TreasuryStockCommonMember2024-06-300000883984us-gaap:RetainedEarningsMember2024-06-300000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000883984icui:CommonStockSharesMember2022-12-310000883984us-gaap:CommonStockMember2022-12-310000883984us-gaap:AdditionalPaidInCapitalMember2022-12-310000883984us-gaap:TreasuryStockCommonMember2022-12-310000883984us-gaap:RetainedEarningsMember2022-12-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100008839842022-12-310000883984icui:CommonStockSharesMember2023-01-012023-03-310000883984us-gaap:CommonStockMember2023-01-012023-03-310000883984us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000883984us-gaap:TreasuryStockCommonMember2023-01-012023-03-3100008839842023-01-012023-03-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000883984us-gaap:RetainedEarningsMember2023-01-012023-03-310000883984icui:CommonStockSharesMember2023-03-310000883984us-gaap:CommonStockMember2023-03-310000883984us-gaap:AdditionalPaidInCapitalMember2023-03-310000883984us-gaap:TreasuryStockCommonMember2023-03-310000883984us-gaap:RetainedEarningsMember2023-03-310000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100008839842023-03-310000883984icui:CommonStockSharesMember2023-04-012023-06-300000883984us-gaap:CommonStockMember2023-04-012023-06-300000883984us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000883984us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000883984us-gaap:RetainedEarningsMember2023-04-012023-06-300000883984icui:CommonStockSharesMember2023-06-300000883984us-gaap:CommonStockMember2023-06-300000883984us-gaap:AdditionalPaidInCapitalMember2023-06-300000883984us-gaap:TreasuryStockCommonMember2023-06-300000883984us-gaap:RetainedEarningsMember2023-06-300000883984us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000008839842023-06-300000883984us-gaap:EmployeeSeveranceMember2023-12-310000883984us-gaap:FacilityClosingMember2023-12-310000883984us-gaap:EmployeeSeveranceMember2024-01-012024-03-310000883984us-gaap:FacilityClosingMember2024-01-012024-03-310000883984us-gaap:EmployeeSeveranceMember2024-03-310000883984us-gaap:FacilityClosingMember2024-03-310000883984us-gaap:EmployeeSeveranceMember2024-04-012024-06-300000883984us-gaap:FacilityClosingMember2024-04-012024-06-300000883984us-gaap:EmployeeSeveranceMember2024-06-300000883984us-gaap:FacilityClosingMember2024-06-300000883984icui:SmithsMedicalMember2023-01-012023-06-300000883984icui:SmithsMedicalMember2023-04-012023-06-300000883984icui:InfusionConsumablesMember2024-04-012024-06-300000883984icui:InfusionConsumablesMember2023-04-012023-06-300000883984icui:InfusionConsumablesMember2024-01-012024-06-300000883984icui:InfusionConsumablesMember2023-01-012023-06-300000883984icui:InfusionSystemsMember2024-04-012024-06-300000883984icui:InfusionSystemsMember2023-04-012023-06-300000883984icui:InfusionSystemsMember2024-01-012024-06-300000883984icui:InfusionSystemsMember2023-01-012023-06-300000883984icui:VitalCareMember2024-04-012024-06-300000883984icui:VitalCareMember2023-04-012023-06-300000883984icui:VitalCareMember2024-01-012024-06-300000883984icui:VitalCareMember2023-01-012023-06-300000883984country:US2024-04-012024-06-300000883984country:US2023-04-012023-06-300000883984country:US2024-01-012024-06-300000883984country:US2023-01-012023-06-300000883984us-gaap:EMEAMember2024-04-012024-06-300000883984us-gaap:EMEAMember2023-04-012023-06-300000883984us-gaap:EMEAMember2024-01-012024-06-300000883984us-gaap:EMEAMember2023-01-012023-06-300000883984srt:AsiaPacificMember2024-04-012024-06-300000883984srt:AsiaPacificMember2023-04-012023-06-300000883984srt:AsiaPacificMember2024-01-012024-06-300000883984srt:AsiaPacificMember2023-01-012023-06-300000883984icui:OtherforeigncountriesMember2024-04-012024-06-300000883984icui:OtherforeigncountriesMember2023-04-012023-06-300000883984icui:OtherforeigncountriesMember2024-01-012024-06-300000883984icui:OtherforeigncountriesMember2023-01-012023-06-300000883984icui:EquipmentrevenueMember2024-01-012024-06-300000883984icui:SoftwarerevenueMember2024-01-012024-06-300000883984icui:GovernmentGrantRevenueMember2024-01-012024-06-300000883984icui:OtherDeferredRevenueMember2024-01-012024-06-300000883984icui:EquipmentrevenueMember2023-01-012023-06-300000883984icui:SoftwarerevenueMember2023-01-012023-06-300000883984icui:GovernmentGrantRevenueMember2023-01-012023-06-300000883984icui:OtherDeferredRevenueMember2023-01-012023-06-300000883984icui:EquipmentrevenueMembericui:ShortTermMember2024-06-300000883984icui:EquipmentrevenueMembericui:LongTermMember2024-06-300000883984icui:SoftwarerevenueMembericui:ShortTermMember2024-06-300000883984icui:SoftwarerevenueMembericui:LongTermMember2024-06-300000883984icui:GovernmentGrantRevenueMembericui:ShortTermMember2024-06-300000883984icui:GovernmentGrantRevenueMembericui:LongTermMember2024-06-300000883984icui:OtherDeferredRevenueMembericui:ShortTermMember2024-06-300000883984icui:OtherDeferredRevenueMembericui:LongTermMember2024-06-300000883984icui:ShortTermMember2024-06-300000883984icui:LongTermMember2024-06-300000883984srt:MinimumMember2024-06-300000883984srt:MaximumMember2024-06-300000883984currency:EUR2024-06-300000883984currency:JPY2024-06-300000883984currency:CNY2024-06-300000883984currency:CAD2024-06-300000883984currency:AUD2024-06-300000883984currency:USD2024-06-300000883984icui:OtherCurrenciesMember2024-06-300000883984us-gaap:InterestRateSwapMembericui:TermLoanAMember2022-06-300000883984us-gaap:InterestRateSwapMembericui:TermLoanAMember2024-06-300000883984us-gaap:InterestRateSwapMembericui:TermLoanBMember2022-06-300000883984us-gaap:InterestRateSwapMembericui:TermLoanBMember2024-06-300000883984us-gaap:InterestRateSwapMembericui:Swap3TermLoanABMember2024-06-300000883984us-gaap:InterestRateSwapMembericui:Swap3Member2024-06-300000883984us-gaap:ForeignExchangeContractMember2024-06-300000883984us-gaap:InterestRateSwapMember2024-06-300000883984us-gaap:ForeignExchangeContractMember2023-12-310000883984us-gaap:InterestRateSwapMember2023-12-310000883984us-gaap:ForeignExchangeContractMember2024-04-012024-06-300000883984us-gaap:ForeignExchangeContractMember2023-04-012023-06-300000883984us-gaap:ForeignExchangeContractMember2024-01-012024-06-300000883984us-gaap:ForeignExchangeContractMember2023-01-012023-06-300000883984us-gaap:InterestRateSwapMember2024-04-012024-06-300000883984us-gaap:InterestRateSwapMember2023-04-012023-06-300000883984us-gaap:InterestRateSwapMember2024-01-012024-06-300000883984us-gaap:InterestRateSwapMember2023-01-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:TradingRevenueMember2024-04-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:TradingRevenueMember2023-04-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:TradingRevenueMember2024-01-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:TradingRevenueMember2023-01-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-04-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-04-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-04-012024-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000883984us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-06-300000883984us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-01-012024-06-300000883984us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-04-012024-06-300000883984us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000883984us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-01-012023-06-300000883984us-gaap:CashFlowHedgingMember2024-04-012024-06-300000883984us-gaap:CashFlowHedgingMember2023-04-012023-06-300000883984us-gaap:CashFlowHedgingMember2024-01-012024-06-300000883984us-gaap:CashFlowHedgingMember2023-01-012023-06-300000883984icui:SmithsMedicalMember2024-04-012024-06-300000883984icui:SmithsMedicalMember2022-01-060000883984icui:SmithsMedicalMember2024-06-300000883984icui:ForeignInfusionSystemSupplierMember2024-04-012024-06-300000883984icui:ForeignInfusionSystemSupplierMember2024-06-300000883984us-gaap:LiabilityMembericui:InternationalDistributorMember2024-01-012024-06-300000883984us-gaap:LiabilityMembericui:InternationalDistributorMember2024-06-300000883984icui:SmithsMedicalForeignInfusionSystemsSupplierMember2023-12-310000883984icui:SmithsMedicalForeignInfusionSystemsSupplierMember2024-03-310000883984icui:SmithsMedicalForeignInfusionSystemsSupplierMember2024-04-012024-06-300000883984icui:SmithsMedicalForeignInfusionSystemsSupplierMember2023-03-310000883984icui:SmithsMedicalForeignInfusionSystemsSupplierMember2023-06-300000883984us-gaap:MeasurementInputPriceVolatilityMembericui:SmithsMedicalMember2024-06-300000883984us-gaap:MeasurementInputPriceVolatilityMembericui:SmithsMedicalMember2023-12-310000883984us-gaap:MeasurementInputRiskFreeInterestRateMembericui:SmithsMedicalMember2024-06-300000883984us-gaap:MeasurementInputRiskFreeInterestRateMembericui:SmithsMedicalMember2023-12-310000883984icui:CurrentMember2024-06-300000883984icui:CurrentMemberus-gaap:FairValueInputsLevel1Member2024-06-300000883984icui:CurrentMemberus-gaap:FairValueInputsLevel2Member2024-06-300000883984icui:CurrentMemberus-gaap:FairValueInputsLevel3Member2024-06-300000883984icui:NoncurrentMember2024-06-300000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel1Member2024-06-300000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel2Member2024-06-300000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel3Member2024-06-300000883984us-gaap:FairValueInputsLevel1Member2024-06-300000883984us-gaap:FairValueInputsLevel2Member2024-06-300000883984us-gaap:FairValueInputsLevel3Member2024-06-300000883984icui:STEarnoutLiabilityMember2024-06-300000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel1Member2024-06-300000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel2Member2024-06-300000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel3Member2024-06-300000883984icui:EarnoutliabilityMember2024-06-300000883984icui:EarnoutliabilityMemberus-gaap:FairValueInputsLevel1Member2024-06-300000883984icui:EarnoutliabilityMemberus-gaap:FairValueInputsLevel2Member2024-06-300000883984icui:EarnoutliabilityMemberus-gaap:FairValueInputsLevel3Member2024-06-300000883984us-gaap:LiabilitiesTotalMember2024-06-300000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel1Member2024-06-300000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel2Member2024-06-300000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel3Member2024-06-300000883984us-gaap:CorporateBondSecuritiesMember2023-12-310000883984us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2023-12-310000883984us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310000883984us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2023-12-310000883984icui:CurrentMember2023-12-310000883984icui:CurrentMemberus-gaap:FairValueInputsLevel1Member2023-12-310000883984icui:CurrentMemberus-gaap:FairValueInputsLevel2Member2023-12-310000883984icui:CurrentMemberus-gaap:FairValueInputsLevel3Member2023-12-310000883984icui:NoncurrentMember2023-12-310000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel1Member2023-12-310000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel2Member2023-12-310000883984icui:NoncurrentMemberus-gaap:FairValueInputsLevel3Member2023-12-310000883984us-gaap:FairValueInputsLevel1Member2023-12-310000883984us-gaap:FairValueInputsLevel2Member2023-12-310000883984us-gaap:FairValueInputsLevel3Member2023-12-310000883984icui:STEarnoutLiabilityMember2023-12-310000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel1Member2023-12-310000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel2Member2023-12-310000883984icui:STEarnoutLiabilityMemberus-gaap:FairValueInputsLevel3Member2023-12-310000883984icui:EarnoutliabilityMember2023-12-310000883984us-gaap:FairValueInputsLevel1Membericui:EarnoutliabilityMember2023-12-310000883984icui:EarnoutliabilityMemberus-gaap:FairValueInputsLevel2Member2023-12-310000883984icui:EarnoutliabilityMemberus-gaap:FairValueInputsLevel3Member2023-12-310000883984us-gaap:LiabilitiesTotalMember2023-12-310000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel1Member2023-12-310000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel2Member2023-12-310000883984us-gaap:LiabilitiesTotalMemberus-gaap:FairValueInputsLevel3Member2023-12-310000883984us-gaap:CorporateBondSecuritiesMember2023-01-012023-12-310000883984icui:NonPublicCompanyMember2024-06-300000883984us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-06-300000883984us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000883984us-gaap:PatentsMember2024-06-300000883984us-gaap:CustomerContractsMember2024-06-300000883984us-gaap:CustomerRelatedIntangibleAssetsMember2024-06-300000883984us-gaap:TrademarksMember2024-06-300000883984us-gaap:TradeNamesMember2024-06-300000883984us-gaap:DevelopedTechnologyRightsMember2024-06-300000883984us-gaap:NoncompeteAgreementsMember2024-06-300000883984us-gaap:PatentsMember2023-12-310000883984us-gaap:CustomerContractsMember2023-12-310000883984us-gaap:CustomerRelatedIntangibleAssetsMember2023-12-310000883984us-gaap:TrademarksMember2023-12-310000883984us-gaap:TradeNamesMember2023-12-310000883984us-gaap:DevelopedTechnologyRightsMember2023-12-310000883984us-gaap:NoncompeteAgreementsMember2023-12-310000883984us-gaap:ForeignExchangeMember2024-06-300000883984us-gaap:ForeignExchangeMember2023-12-310000883984icui:LongTermMember2023-12-310000883984icui:TermLoanAMember2024-04-012024-06-300000883984icui:TermLoanBMember2024-04-012024-06-300000883984us-gaap:RevolvingCreditFacilityMember2024-06-300000883984icui:TermLoanAMember2024-06-300000883984icui:TermLoanBMember2024-06-300000883984icui:Greaterthan400to100Membericui:TermLoanAMember2024-06-300000883984icui:Greaterthan400to100Member2024-04-012024-06-300000883984icui:LessThanOrEqualTo400To100ButGreaterThan300To100Membericui:TermLoanAMember2024-06-300000883984icui:LessThanOrEqualTo400To100ButGreaterThan300To100Member2024-04-012024-06-300000883984icui:LessThanOrEqual300To100ButGreaterThan250to100Membericui:TermLoanAMember2024-06-300000883984icui:LessThanOrEqual300To100ButGreaterThan250to100Member2024-04-012024-06-300000883984icui:LessThanOrEqualTo250To100ButGreaterThan200To100Membericui:TermLoanAMember2024-06-300000883984icui:LessThanOrEqualTo250To100ButGreaterThan200To100Member2024-04-012024-06-300000883984icui:LessThanOrEqualTo200To100Membericui:TermLoanAMember2024-06-300000883984icui:LessThanOrEqualTo200To100Member2024-04-012024-06-300000883984icui:GreaterThan275To100Membericui:TermLoanBMember2024-06-300000883984icui:LessThan275To100Membericui:TermLoanBMember2024-06-300000883984icui:TermLoanAMember2023-01-012023-12-310000883984icui:TermLoanAMember2023-12-310000883984icui:TermLoanBMember2023-01-012023-12-310000883984icui:TermLoanBMember2023-12-310000883984us-gaap:RevolvingCreditFacilityMember2024-04-012024-06-300000883984us-gaap:RevolvingCreditFacilityMember2023-01-012023-12-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-12-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-03-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-03-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-04-012024-06-300000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-04-012024-06-300000883984us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-06-300000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000883984us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-12-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-03-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-03-310000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000883984us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-04-012023-06-300000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000883984us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000883984us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-06-300000883984us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000883984icui:InternationalDistributorMember2024-01-012024-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended: June 30, 2024
 or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from:              to
 
Commission File No.: 001-34634
 ICU MEDICAL, INC.
(Exact name of registrant as specified in its charter) 
Delaware 33-0022692
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
951 Calle Amanecer,San Clemente,California92673
(Address of principal executive offices)(Zip Code)
 (949) 366-2183
(Registrant’s telephone number including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC
(Global Select Market)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x  No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. 
Large accelerated filerx Accelerated filer
Non-accelerated filer Smaller reporting company
 Emerging growth company
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):  Yes  No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
 
Class Outstanding at July 31, 2024
Common 24,425,279




ICU MEDICAL, INC. AND SUBSIDIARIES
Form 10-Q
June 30, 2024

Table of Contents
 Page Number
PART I.
Item 1. 
 
Condensed Consolidated Balance Sheets at June 30, 2024 and December 31, 2023
 
 
Item 2.
Item 3.
Item 4.
PART II. 
Item 1.
Item1A.
Item 2.
Item 5.
Item 6.




Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present and historical fact, contained in this Quarterly Report on Form 10-Q, including, without limitation, statements regarding our future results of operations and financial position, business strategy and approach, expected capital expenditures; expected impacts from new accounting and tax regulations; as well as plans and objectives of management for future operations may be forward-looking statements. Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as “aim,” “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

The forward looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including without limitation, the following:

our failure to compete successfully with our competitors and maintain market share;
significant decline in demand for our products;
our inability to fund substantial investment in product development and recover such investment through commercial product sales;
prolonged periods of inflation, rising interest rates and the impact of foreign currency exchange rates as a result of the current global macroeconomic and geopolitical conditions, for example, armed conflicts between Ukraine and Russia and in Israel;
our exposure to risks related to foreign currency exchange rates;
continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement;
disruptions at the FDA, other government agencies or notified bodies caused by funding shortages or global health concerns;
failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data;
damage to any of our manufacturing facilities or disruption to our supply chain network;
our dependence on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers;
our failure to achieve expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts;
significant sales through our distributors;
additional risks from international sales, related to competition with larger international companies and established local companies and our possibly higher cost structure;
any significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs;
actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards, or certain fraud and abuse and transparency laws;
our failure to defend and enforce our patents or other proprietary rights and the cost of enforcing and of defending patent claims or claims of other proprietary rights; and expiration of our patents;
our failure to effectively manage our growth and change to our business resulting from the Smiths Medical acquisition or any other future acquisitions; and
the actual impact of the Smiths Medical acquisition on our financial results and our use of a significant portion of our cash on hand and incurrence of a substantial amount of debt to finance the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.

For a more detailed discussion of these factors, see the information under the sections entitled “Summary Risk Factors,” Part I. Item 1A. “Risk Factors” and Part II. Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) filed with the Securities and Exchange Commission (the “SEC”), and the sections in this Quarterly
1


Report on Form 10-Q entitled Part II. Item 1A “Risk Factors” and Part I. Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in each case as updated by our periodic filings with the SEC.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
2


PART I - FINANCIAL INFORMATION
Item1.Financial Statements (Unaudited)

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value data and treasury shares) 
 June 30,
2024
December 31,
2023
 (Unaudited)(1)
ASSETS  
CURRENT ASSETS:  
Cash and cash equivalents$302,648 $254,222 
Short-term investment securities 501 
TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES302,648 254,723 
Accounts receivable, net of allowance for doubtful accounts $11,772 at June 30, 2024 and $11,064 at December 31, 2023
151,765 161,566 
Inventories682,870 709,360 
Prepaid income taxes17,883 21,983 
Prepaid expenses and other current assets80,825 73,640 
TOTAL CURRENT ASSETS1,235,991 1,221,272 
PROPERTY, PLANT AND EQUIPMENT, net594,085 612,909 
OPERATING LEASE RIGHT-OF-USE ASSETS66,408 69,909 
GOODWILL1,450,935 1,472,446 
INTANGIBLE ASSETS, net805,794 870,588 
DEFERRED INCOME TAXES38,861 37,295 
OTHER ASSETS94,593 94,020 
TOTAL ASSETS$4,286,667 $4,378,439 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
CURRENT LIABILITIES:  
Accounts payable$155,515 $150,030 
Accrued liabilities299,751 268,215 
Current portion of long-term debt51,000 51,000 
Income tax payable4,141 7,714 
Contingent earn-out liability1,500 4,879 
TOTAL CURRENT LIABILITIES511,907 481,838 
CONTINGENT EARN-OUT LIABILITY3,947 3,991 
LONG-TERM DEBT1,554,822 1,577,770 
OTHER LONG-TERM LIABILITIES91,356 100,497 
DEFERRED INCOME TAXES53,794 55,873 
INCOME TAX LIABILITY33,029 35,060 
COMMITMENTS AND CONTINGENCIES (Note 18)  
STOCKHOLDERS’ EQUITY:  
Convertible preferred stock, $1.00 par value; Authorized — 500 shares; Issued and outstanding — none
  
Common stock, $0.10 par value; Authorized — 80,000 shares; Issued — 24,430 shares at June 30, 2024 and 24,144 shares at December 31, 2023; and outstanding — 24,425 shares at June 30, 2024 and 24,141 shares at December 31, 2023
2,443 2,414 
Additional paid-in capital1,380,703 1,366,493 
Treasury stock, at cost (5,128 and 2,428 shares, respectively)
(518)(262)
Retained earnings746,969 807,846 
Accumulated other comprehensive loss(91,785)(53,081)
TOTAL STOCKHOLDERS' EQUITY2,037,812 2,123,410 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$4,286,667 $4,378,439 
______________________________________________________
(1) December 31, 2023 balances were derived from audited consolidated financial statements.
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share data)
 
 Three months ended
June 30,
Six months ended
June 30,
 2024202320242023
TOTAL REVENUES$596,455 $549,310 $1,163,110 $1,117,959 
COST OF GOODS SOLD389,027 356,983 770,438 733,591 
GROSS PROFIT207,428 192,327 392,672 384,368 
OPERATING EXPENSES:  
Selling, general and administrative159,549 150,895 317,206 303,467 
Research and development23,390 22,302 45,232 42,063 
Restructuring, strategic transaction and integration17,136 12,354 33,241 23,367 
Change in fair value of contingent earn-out(339)4,016 (44)3,316 
TOTAL OPERATING EXPENSES199,736 189,567 395,635 372,213 
INCOME (LOSS) FROM OPERATIONS7,692 2,760 (2,963)12,155 
INTEREST EXPENSE, NET(23,841)(24,121)(47,613)(46,636)
OTHER EXPENSE, NET(3,384)(1,502)(5,725)(1,771)
LOSS BEFORE INCOME TAXES(19,533)(22,863)(56,301)(36,252)
(PROVISION) BENEFIT FOR INCOME TAXES(1,873)12,929 (4,576)16,506 
NET LOSS$(21,406)$(9,934)$(60,877)$(19,746)
NET LOSS PER SHARE  
Basic$(0.88)$(0.41)$(2.51)$(0.82)
Diluted$(0.88)$(0.41)$(2.51)$(0.82)
WEIGHTED AVERAGE NUMBER OF SHARES  
Basic24,393 24,075 24,295 24,045 
Diluted24,393 24,075 24,295 24,045 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited)
(In thousands)
 
 Three months ended
June 30,
Six months ended
June 30,
 2024202320242023
NET LOSS$(21,406)$(9,934)$(60,877)$(19,746)
Other comprehensive (loss) income, net of tax:
Cash flow hedge adjustments, net of tax of $(2,054) and $1,687 for the three months ended June 30, 2024 and 2023, respectively, and $(25) and $(57) for the six months ended June 30, 2024 and 2023, respectively.
(6,382)5,274 (22)(303)
Foreign currency translation adjustment, net of tax of $0 for all periods
(15,865)7,569 (38,682)32,552 
Other adjustments, net of tax of $0 for all periods
 (34) (65)
Other comprehensive (loss) income, net of tax(22,247)12,809 (38,704)32,184 
COMPREHENSIVE (LOSS) INCOME$(43,653)$2,875 $(99,581)$12,438 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)
(Amounts in thousands)


Common StockAdditional
Paid-in
Capital
Treasury
Stock
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
SharesAmountTotal
Balance, January 1, 202424,144 $2,414 $1,366,493 $(262)$807,846 $(53,081)$2,123,410 
Issuance of restricted stock and exercise of stock options378 27 (6,847)6,970 — — 150 
Tax withholding payments related to net share settlement of equity awards(110)— — (11,400)— — (11,400)
Stock compensation— — 11,598 — — — 11,598 
Other comprehensive loss, net of tax— —  — — (16,457)(16,457)
Net loss— — — — (39,471)— (39,471)
Balance, March 31, 202424,412 $2,441 $1,371,244 $(4,692)$768,375 $(69,538)$2,067,830 
Issuance of restricted stock and exercise of stock options21 2 (1,537)4,459 — — 2,924 
Tax withholding payments related to net share settlement of equity awards(3)— — (285)— — (285)
Stock compensation— — 10,998 — — — 10,998 
Other comprehensive loss, net of tax— — (2)— — (22,247)(22,249)
Net loss— — — — (21,406)— (21,406)
Balance, June 30, 202424,430 $2,443 $1,380,703 $(518)$746,969 $(91,785)$2,037,812 



 Common StockAdditional
Paid-in
Capital
Treasury
Stock
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
SharesAmountTotal
Balance, January 1, 202323,995 $2,399 $1,331,249 $(243)$837,501 $(80,978)$2,089,928 
Issuance of restricted stock and exercise of stock options172 12 (503)662 — — 171 
Tax withholding payments related to net share settlement of equity awards(53)— — (8,425)— — (8,425)
Stock compensation— — 9,158 — — — 9,158 
Other comprehensive income, net of tax— — 4 — — 19,375 19,379 
Net loss— — — — (9,812)— (9,812)
Balance, March 31, 202324,114 $2,411 $1,339,908 $(8,006)$827,689 $(61,603)$2,100,399 
Issuance of restricted stock and exercise of stock options2  (4,626)6,688 — — 2,062 
Tax withholding payments related to net share settlement of equity awards(2)— — (293)— — (293)
Stock compensation— — 9,773 — — — 9,773 
Other comprehensive income, net of tax— — 2 — — 12,809 12,811 
Net loss— — — — (9,934)— (9,934)
Balance, June 30, 202324,114 $2,411 $1,345,057 $(1,611)$817,755 $(48,794)$2,114,818 
6

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands) 

 Six months ended
June 30,
 20242023
CASH FLOWS FROM OPERATING ACTIVITIES:  
Net loss$(60,877)$(19,746)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
Depreciation and amortization110,844 113,244 
Noncash lease expense10,524 11,110 
Provision for doubtful accounts1,370 399 
Provision for warranty, returns and field action(2,458)7,070 
Stock compensation22,596 18,931 
(Gain) loss on disposal of property, plant and equipment and other assets(78)1,019 
Debt issuance costs amortization3,411 3,404 
Change in fair value of contingent earn-out liability(44)3,316 
Usage of spare parts8,944 10,056 
Other4,925 2,917 
Changes in operating assets and liabilities, net of amounts acquired: 
Accounts receivable6,715 46,796 
Inventories21,095 (76,040)
Prepaid expenses and other current assets(12,638)2,983 
Other assets(11,124)(12,698)
Accounts payable9,432 (46,864)
Accrued liabilities20,245 (104)
Income taxes, including excess tax benefits and deferred income taxes(5,138)(26,022)
Net cash provided by operating activities127,744 39,771 
CASH FLOWS FROM INVESTING ACTIVITIES:  
Purchases of property, plant and equipment(35,382)(32,489)
Proceeds from sale of assets692 1,431 
Intangible asset additions(5,364)(4,651)
Proceeds from sale and maturities of investment securities500 2,920 
Net cash used in investing activities(39,554)(32,789)
CASH FLOWS FROM FINANCING ACTIVITIES:  
Principal repayments of long-term debt(25,500)(14,813)
Proceeds from exercise of stock options3,074 2,233 
Payments on finance leases(518)(436)
Payments of contingent earn-out liability(2,600) 
Tax withholding payments related to net share settlement of equity awards(11,685)(8,718)
Net cash used in financing activities(37,229)(21,734)
Effect of exchange rate changes on cash(2,535)1,855 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS48,426 (12,897)
CASH AND CASH EQUIVALENTS, beginning of period254,222 208,784 
CASH AND CASH EQUIVALENTS, end of period$302,648 $195,887 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.




7

ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - CONTINUED
(In thousands)

Six months ended
June 30,
20242023
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:
  Purchases of property, plant, and equipment in accounts payable$3,868 $2,362 

The accompanying notes are an integral part of these condensed consolidated financial statements.
8

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)



Note 1:Basis of Presentation
 
The accompanying unaudited interim condensed consolidated financial statements of ICU Medical, Inc., ("ICU" or the "Company"), a Delaware corporation, have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.") and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU for the year ended December 31, 2023.
 
We develop, manufacture and sell innovative medical products used in infusion therapy, vascular access, and vital care applications. ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. We sell the majority of our products globally through our direct sales force and through independent distributors throughout the U.S. and internationally. We also sell certain products on an original equipment manufacturer basis to other medical device manufacturers. All subsidiaries are wholly owned and are included in the condensed consolidated financial statements. All intercompany balances and transactions have been eliminated.

Certain reclassifications have been made to the prior year cash flows from operating activities within the condensed consolidated statements of cash flows to conform to the presentation used in the current year. We reclassified bond premium amortization to other. The reclassification had no impact on cash flows from operating activities as previously reported.

Note 2:    New Accounting Pronouncements

Recently Issued Accounting Standards

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative. The amendments in this update modify the disclosure or presentation requirements of a variety of Topics in the Accounting Standards Codification ("ASC") in response to the SEC’s Release No. 33-10532, Disclosure Update and Simplification Initiative, and align the ASC’s requirements with the SEC’s regulations. For entities within the scope, the guidance will be applied prospectively with the effective date for each amendment to be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and will not become effective. We are currently assessing what impact this guidance will have on the Company's consolidated financial statements and related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. The amendments in this update expand disclosures about a public entity’s reportable segments and requires more enhanced information about a reportable segment’s significant expenses, interim segment profit or loss, and a description of how a public entity’s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The amendments clarify that a single reportable segment entity must apply ASC 280 in its entirety. The update will be effective for annual periods beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent interim periods, with early application permitted. We are currently assessing the effect of this update on our consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. The amendments in this update expand disclosures in an entity’s income tax rate reconciliation table and regarding cash taxes paid information. The update will be effective for annual periods beginning after December 15, 2024 and is applicable to our Annual Report on Form 10-K for the fiscal year December 31, 2025, with early application permitted. We are currently assessing the effect of this update on our consolidated financial statements and related disclosures.
        
Note 3: Restructuring, Strategic Transaction and Integration
9

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

    Restructuring, strategic transaction and integration expenses were $17.1 million and $33.2 million for the three and six months ended June 30, 2024, respectively, as compared to $12.4 million and $23.4 million for the three and six months ended June 30, 2023, respectively.

Restructuring

    During the three and six months ended June 30, 2024, restructuring charges were $7.7 million and $13.0 million, respectively, as compared to $1.3 million and $4.0 million respectively, for the three and six months ended June 30, 2023 and were primarily related to severance costs for the periods. The restructuring charges for the six months ended June 30, 2023 is net of $0.9 million related to facility closures costs and severance costs that were reversed during the first fiscal quarter of 2023.     
    
The following table summarizes the activity in our restructuring-related accrual by major type of cost for the six months ended June 30, 2024 (in thousands):
Severance Pay and BenefitsRetention and Facility Closure CostsTotal
Accrued balance, January 1, 2024$2,811 $757 $3,568 
Charges incurred5,065 295 5,360 
Payments(2,760)(184)(2,944)
Other(1)
(41) (41)
Currency translation(13)(7)(20)
Accrued balance, March 31, 2024
$5,062 $861 $5,923 
Charges incurred7,712  7,712 
Payments(3,678) (3,678)
Currency translation(33) (33)
Accrued balance, June 30, 2024
$9,063 $861 $9,924 
__________________________
(1) Relates to prior year accrued restructuring charges for estimated severances costs that will not be utilized and were reversed during the three months ended March 31, 2024.

Strategic Transaction and Integration Expenses

    We incurred and expensed $9.4 million and $20.2 million in strategic transaction and integration expenses during the three and six months ended June 30, 2024, respectively, as compared to $11.1 million and $19.4 million in strategic transaction and integration expenses during the three and six months ended June 30, 2023, respectively, which are included in restructuring, strategic transaction and integration expenses in our condensed consolidated statements of operations. The strategic transaction and integration expenses during the three and six months ended June 30, 2024 and 2023 were primarily related to consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022.

Related-party Transition Services Expenses

Smiths Group plc ("Smiths") became a related party to us when we issued 2.5 million shares of our common stock as partial consideration to Smiths for the acquisition of Smiths Medical 2020 Limited ("Smiths Medical"). Additionally, we entered into a transition services agreement ("TSA") with certain Smiths legal entities. The TSA included certain information technology, human resource and tax support services for an initial term of twelve months with the option to extend up to 24 months. During the three and six months ended June 30, 2023, we expensed $3.9 million and $7.9 million, respectively, for services provided by Smiths under the TSA. Since December 31, 2023, there were no services being provided under the TSA and we had no remaining related-party open payables as of December 31, 2023.

Note 4: Revenue

Revenue Recognition

10

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
    Our business units are Consumables, Infusion Systems and Vital Care. The vast majority of our sales of products within these business units are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. Our software license renewals are considered to be transferred to a customer at a point in time at the start of each renewal period, therefore revenue is recognized at that time.

    Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We include variable consideration in net sales only to the extent that a significant reversal in revenue is not probable when the uncertainty is resolved. Our variable consideration includes distributor chargebacks, product returns and end customer rebates with distributor chargebacks representing the majority and subject to the greatest judgment.

Chargebacks are the difference between the prices we charge our distribution customers at the time they purchase our products and the contracted prices we have with the end customer, most often in the U.S. and Canada. When a distributor sells our products to one of our contracted end customers, the distributor typically will claim a refund from us for the chargeback amount which we process as a credit to the distributor.

In estimating the transaction price to present as net revenue for sales to distributors, we must estimate the expected chargeback amount that we will refund to the distributor after they sell our product to a contracted end customer. Determining the appropriate chargeback reserve requires judgment around the following assumptions:

(i) The estimated chargeback amount (the difference between the price we invoice the distributor and the contractually agreed price with specified end customers); and

(ii) The estimated period of time between the sale to the distributor and the receipt of a chargeback claim.

For purposes of estimating the expected chargeback amount, we utilize actual recent historical chargebacks paid to the specific distributor for similar products as determined at either a product or product-family level. While individual chargeback rates can vary significantly depending on the product and contracted prices with distributors and end customers, our chargeback reserve estimate is not overly sensitive to those individual price changes due to the long-term nature of our distributor and end customer contracts as well as consistency in purchasing patterns. Additionally, the use of the actual chargeback history to calculate an average chargeback rate has historically resulted in a reasonable estimation of overall current contract rates.

For purposes of estimating the period of time between the sale to the distributor and the receipt of a chargeback claim, we utilize several sources of information including actual inventory quantities of our products on hand at distributors. This inventory on hand information is received from the distributors or, when specific quantities are not provided, estimated by using the targeted days of inventory on hand for distributors. Historical experience of actual chargebacks paid has indicated that use of this information has reasonable predictive value of outstanding chargebacks and accounts for the variability of purchasing
patterns and expected timing and volume of sales to end customers. The value of the chargeback reserve generally represents approximately two months of obligation due to the timing difference between the initial sale to a distributor and the processing of a chargeback claim after the product is sold to the end customer.

The chargeback reserve estimates change from period-to-period primarily based on changes in revenue from/and the inventory levels of distributors. Our judgments regarding the information used to calculate the chargeback reserve are consistent from period to period; however, on a regular basis, we evaluate the adequacy of the chargeback reserve to reassess and ensure that the variable consideration is appropriately constrained, and the likelihood of future revenue reversal is not probable. We use metrics including chargeback provision as a percentage of gross revenue, movements in inventory on hand at distributors, trends in accrued versus paid chargebacks and impacts from price changes and similar metrics.

The chargeback reserve reflects a reasonable estimate of the amount of consideration using the expected value method and is recorded as a reduction of accounts receivable, net on the consolidated balance sheets.

    We also offer certain volume-based rebates to both our distribution and end customers, which is recorded as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time, including current contractual requirements, our historical experience with each customer and forecasted customer purchasing patterns, to estimate the most likely rebate amount.

We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide
11

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative stand-alone selling price, and recognize revenue over the period the warranty service is provided.

Arrangements with Multiple Performance Obligations

We also enter into arrangements which include multiple performance obligations. The most significant judgments related to these arrangements include:

Identifying the various performance obligations of these arrangements.
Estimating the relative standalone selling price of each performance obligation, typically using a directly observable method or calculated on a cost plus margin basis method.

Revenue Disaggregated

The following table represents our revenues disaggregated by product line (in thousands):

Three months ended
June 30,
Six months ended
June 30,
Product line2024202320242023
Consumables$261,816 236,976 505,855 473,098 
Infusion Systems163,638 153,142 320,976 314,855 
Vital Care171,001 159,192 336,279 330,006 
Total Revenues$596,455 $549,310 $1,163,110 $1,117,959 

For the three and six months ended June 30, 2024 and 2023, net sales to Medline made up approximately 17% and 15% of total revenues, respectively.

The following table represents our revenues disaggregated by geography (in thousands):
Three months ended
June 30,
Six months ended
June 30,
Geography2024202320242023
United States$383,140 $347,866 $749,295 $707,053 
Europe, the Middle East and Africa95,310 89,994 193,699 188,980 
APAC61,224 60,031 113,077 118,655 
Other Foreign56,781 51,419 107,039 103,271 
Total Revenues$596,455 $549,310 $1,163,110 $1,117,959 
    
Contract Balances

    The following table presents the changes in our contract balances for the six months ended June 30, 2024 and 2023 (in thousands):
12

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contract Liabilities
Beginning balance, January 1, 2024$(42,177)
Equipment revenue recognized16,951 
Equipment revenue deferred due to implementation(20,593)
Software revenue recognized10,232 
Software revenue deferred due to implementation(10,427)
Government grant income recognized(1)
1,029 
Government grant income deferred 
Other deferred revenue(423)
Other deferred revenue recognized1,602 
Ending balance, June 30, 2024
$(43,806)
Beginning balance, January 1, 2023$(45,866)
Equipment revenue recognized16,793 
Equipment revenue deferred due to implementation(16,625)
Software revenue recognized9,041 
Software revenue deferred due to implementation(8,875)
Government grant income deferred(944)
Government grant income recognized(1)
647 
Other deferred revenue(688)
Other deferred revenue recognized3,514 
Ending balance, June 30, 2023
$(43,003)
____________________________
(1) The government grant income deferred is amortized over the life of the related depreciable asset as a reduction to depreciation expense.
Our contract liabilities are included in accrued liabilities or other long-term liabilities in our condensed consolidated balance sheet based on the expected timing of revenue recognition.    

As of June 30, 2024, revenue from remaining performance obligations is as follows:

Recognition Timing
(in thousands)< 12 Months> 12 Months
Equipment deferred revenue$(21,226)$(937)
Software deferred revenue(9,783)(489)
Government grant deferred income(1)
(2,065)(8,384)
Other deferred revenue(2)
(717)(205)
Total $(33,791)$(10,015)
_________________________________
(1) The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense.
(2) Other deferred revenue includes pump development programs, purchased training and extended warranty.
Note 5: Leases
    
    We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our condensed consolidated balance sheets. Our lease liabilities are included in accrued liabilities and other long-term liabilities on our condensed
13

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.

    Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate; therefore, we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have stated lease payments, which may include fixed rental increases. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
    
    Our leases are for corporate, research and development and sales and support offices, manufacturing and distribution facilities, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms because we determined the exercise of options to extend is not reasonably certain.
    
The following table presents the components of our lease cost (in thousands):
Three months ended
June 30,
Six months ended
June 30,
2024202320242023
Operating lease cost$5,638 $6,043 $11,452 $12,193 
Finance lease cost — interest47 31 80 60 
Finance lease cost — reduction of ROU asset301 254 555 479 
Short-term lease cost 13  26 
Total lease cost $5,986 $6,341 $12,087 $12,758 
    
Interest expense on our finance leases is included in interest expense, net in our condensed consolidated statements of operations. The reduction of the operating and finance ROU assets is included as noncash lease expense in costs of goods sold and selling, general and administrative expenses in our condensed consolidated statements of operations.    

The following table presents the supplemental cash flow information related to our leases (in thousands):
Six months ended
June 30,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$11,730 $12,336 
Operating cash flows from finance leases$80 $60 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$8,650 $10,153 
Finance leases$1,202 $804 
    
The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):
14

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of
June 30, 2024December 31, 2023
Operating leases
Operating lease right-of-use assets$66,408$69,909
Accrued liabilities$17,915$20,161
Other long-term liabilities52,17952,972
Total operating lease liabilities$70,094$73,133
Weighted-Average Remaining Lease Term
Operating leases5.6 years5.6 years
Weighted-Average Discount Rate
Operating leases4.64 %4.31 %
    
The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):
As of
June 30, 2024December 31, 2023
Finance leases
Finance lease right-of-use assets$3,273$2,707
Accrued liabilities$998$860
Other long-term liabilities2,3971,954
Total finance lease liabilities$3,395$2,814
Weighted-Average Remaining Lease Term
Finance leases4.0 years4.1 years
Weighted-Average Discount Rate
Finance leases5.50 %4.93 %
        
    
15

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of June 30, 2024, the maturities of our operating and finance lease liabilities for each of the next five years and thereafter are approximately (in thousands):
Operating LeasesFinance Leases
Remainder of 2024$11,439 $530 
202518,076 1,086 
202615,747 965 
202711,226 627 
20286,571 305 
20296,793 194 
Thereafter9,196 48 
Total Lease Payments79,048 3,755 
Less imputed interest(8,954)(360)
Total$70,094 $3,395 

Note 6:    Net Loss Per Share
 
Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options and restricted stock units that are anti-dilutive are not included in the treasury stock method calculation. A net loss for the three and six months ended June 30, 2024 and 2023, causes all of the potentially dilutive common shares to be antidilutive, and accordingly, they were not included in the computation of diluted earnings per share and basic and diluted net loss per share are equal for each of these periods.

    The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data): 
 Three months ended
June 30,
Six months ended
June 30,
 2024202320242023
Net loss$(21,406)$(9,934)$(60,877)$(19,746)
Weighted-average number of common shares outstanding (basic)24,393 24,075 24,295 24,045 
Dilutive securities(1)
    
Weighted-average common and common equivalent shares outstanding (diluted)24,393 24,075 24,295 24,045 
EPS — basic$(0.88)$(0.41)$(2.51)$(0.82)
EPS — diluted$(0.88)$(0.41)$(2.51)$(0.82)
Total anti-dilutive stock options and restricted stock awards216162202 72 
_______________________________
(1)    Due to the net loss for the three and six months ended June 30, 2024 and 2023, there are no potentially dilutive common shares included in the computation of diluted earnings per share.

Note 7:    Derivatives and Hedging Activities

Hedge Accounting and Hedging Program

     The purposes of our cash flow hedging programs are to manage the foreign currency exchange rate risk on forecasted revenues and expenses denominated in currencies other than the functional currency of the operating unit, and to manage
16

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
floating interest rate risk associated with future interest payments on the variable-rate term loans issued in 2022. We do not issue derivatives for trading or speculative purposes.

    To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative instruments we utilize, including various foreign exchange contracts and interest rate swaps, are designated and qualify as cash flow hedges. Our derivative instruments are recorded at fair value on the condensed consolidated balance sheets and are classified based on the instrument's maturity date. We record gains or losses from changes in the fair values of the derivative instruments as a component of other comprehensive (loss) income and we reclassify those gains or losses into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, we reclassify the gain or loss on the related derivative instrument from accumulated other comprehensive loss into earnings immediately.

Foreign Currency Exchange Rate Risk

Foreign Exchange Forward Contracts

We enter into foreign exchange forward contracts to hedge a portion of our forecasted foreign currency-denominated revenues and expenses to minimize the effect of foreign exchange rate movements on the related cash flows. These contracts are agreements to buy or sell a quantity of a currency at a predetermined future date and at a predetermined exchange rate. Our foreign exchange forward contracts hedge exposures principally denominated in Mexican Pesos ("MXN"), Euros, Czech Koruna ("CZK"), Japanese Yen ("JPY"), Swedish Krona ("SEK"), Danish Krone ("DKK"), Chinese Renminbi ("CNH"), Canadian Dollar ("CAD"), U.S. Dollar ("USD") and Australian Dollar ("AUD") and have varying maturities with an average term of approximately thirteen months. The total notional amount of these outstanding derivative contracts as of June 30, 2024 was $100.9 million, which included the notional equivalent of $20.6 million in Euros, $9.3 million in JPY, $4.9 million in CNH, $12.7 million in CAD, $10.0 million in AUD, $33.9 million in USD and $9.5 million in other foreign currencies, with terms currently through November 2025.

Floating Interest Rate Risk

In 2022, we entered into interest rate swaps to reduce the interest rate volatility on our variable-rate term loan A and variable-rate term loan B (see Note 16: Long-Term Debt). We exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Effective March 30, 2022, the term loan A swap, as amended, has an initial notional amount of $300.0 million, reducing to $150.0 million evenly on a quarterly basis excluding its final maturity on March 30, 2027. We pay a fixed rate of 1.32% and will receive the greater of 3-months USD Secured Overnight Financing Rate ("SOFR") or (0.15)%. The total notional amount of this outstanding derivative as of June 30, 2024 was approximately $228.9 million. Effective March 30, 2022, the term loan B swap, as amended, has an initial notional amount of $750.0 million, reducing to $46.9 million evenly on a quarterly basis through its final maturity on March 30, 2026. We pay a fixed rate of 1.17% and will receive the greater of 3-months USD SOFR or 0.35%. The total notional amount of this outstanding derivative as of June 30, 2024 was approximately $328.1 million.

In June 2023, we entered into an additional interest rate swap that hedges both term loan A and term loan B interest payments. The total notional amount of the swap is $300.0 million. The hedge matures on June 30, 2028. We pay a fixed rate of 3.88% and will receive 3-months USD SOFR.

These swaps effectively convert the relevant portion of the floating-rate term loans to fixed rates.
    
The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets (in thousands):

17

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Derivatives Designated as Cash Flow Hedging Instruments
Condensed Consolidated Balance Sheet LocationForeign Exchange ContractsInterest Rate SwapsGross Derivatives
As of June 30, 2024
Prepaid expenses and other current assets$3,623 $21,006 $24,629 
Other assets99 9,584 9,683 
Total assets$3,722 $30,590 $34,312 
Accrued liabilities$1,473 $ $1,473 
Other long-term liabilities314  314 
Total liabilities$1,787 $ $1,787 
As of December 31, 2023
Prepaid expenses and other current assets$6,785 $23,065 $29,850 
Other assets673 4,876 5,549 
Total assets$7,458 $27,941 $35,399 
Accrued liabilities$2,590 $ $2,590 
Other long-term liabilities240  240 
Total liabilities$2,830 $ $2,830 


We recognized the following (loss) gains on our derivative instruments designated as cash flow hedges in other comprehensive income before reclassifications to net loss (in thousands):
Gain (Losses) Recognized in Other Comprehensive Income
Three months ended
June 30,
Six months ended
June 30,
2024202320242023
Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts$(3,965)$6,051 $975 $8,503 
Interest rate swaps4,512 11,324 17,905 8,740 
Total derivatives designated as cash flow hedging instruments$547 $17,375 $18,880 $17,243 

The following table presents the effects of our derivative instruments designated as cash flow hedges on the Condensed Consolidated Statements of Operations (in thousands):
18

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Gains (Losses) Reclassified From Accumulated Other Comprehensive (Loss) Income into Net Loss
Three months ended
June 30,
Six months ended
June 30,
Location of Gains (Losses) Recognized in Net Loss2024202320242023
Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contractsTotal revenues$633 $473 $1,333 $(1,448)
Foreign exchange forward contractsCost of goods sold1,059 2,316 2,339 3,816 
Foreign exchange forward contractsOther expense, net(1)   229 
Foreign exchange forward contractsInterest expense(2)   13 
Interest rate swapsInterest expense7,291 7,625 15,255 14,993 
Total derivatives designated as cash flow hedging instruments$8,983 $10,414 $18,927 $17,603 
_______________________________
(1)    Represents location of gain reclassified from accumulated other comprehensive loss into other expense, net as a result of ineffectiveness.
(2)    Represents location of gain reclassified from accumulated other comprehensive loss into interest expense as a result of forecasted transactions no longer probable of occurring.

As of June 30, 2024, we expect an estimated $2.1 million in deferred gains on the outstanding foreign exchange contracts and an estimated $21.9 million in deferred gains on the interest rate swaps will be reclassified from accumulated other comprehensive loss to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.    

Note 8:    Fair Value Measurements
 
    Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value:

Level 1: quoted prices in active markets for identical assets or liabilities;
Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

Contingent Earn-out Liabilities

In 2022, we acquired Smiths Medical with a combination of cash consideration and share consideration issued at closing. Total consideration for the acquisition included a potential earn-out payment of $100.0 million in cash contingent on our common stock achieving a certain volume-weighted average price (the "Price Targets") from the closing date to either the third or fourth anniversary of closing and provided Smiths beneficially owns at least 50.0% of the shares of common stock issued at closing at the time the Price Target is achieved. The initial estimated fair value of the earn-out was determined to be $53.5 million. The initial fair value of the earn-out was determined using a Monte Carlo simulation model. The model utilized several assumptions including volatility and the risk-free interest rate. The assumed volatility is based on the average of the historical volatility of our common stock price and the implied volatility of certain at-the-money traded options. The risk-free interest rate is equal to the yield on U.S. Treasury securities at constant maturity for the period commensurate with the term of the earn-out. At each reporting date subsequent to the acquisition, we remeasure the earn-out liability and recognize any changes in its fair value in our consolidated statements of operations. If the probability of achieving the Price Targets during their respective measurement periods is significantly greater than initially anticipated, the realization of an additional liability and related expense will have a significant impact on our consolidated financial statements in the period recognized. As of December 31, 2023, the estimated fair value of the contingent earn-out was $4.0 million. As of June 30, 2024, the estimated fair value of the contingent earn-out was $3.9 million. During July 2024, Smiths sold 1.2 million common shares of ICU Medical,
19

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Inc. It was issued as partial consideration for the 2022 acquisition of Smiths Medical. The sale of shares when combined with other sales in prior periods renders Smiths unable to achieve the contingent consideration based on certain price targets during the third and fourth anniversary of closing as Smiths no longer meets the required minimum beneficial ownership percentage. Accordingly, the third quarter 2024 valuation of the contingent earn-out will reduce the contingent earn-out's fair market value to zero.

In November 2021, we acquired a small foreign infusion systems supplier. Total consideration for the acquisition included a potential earn-out payment of up to $2.5 million, consisting of (i) a cash payment of $1.0 million contingent on the achievement of certain revenue targets for the annual period ended December 31, 2022 and, separately, (ii) a cash payment of $1.5 million contingent upon obtaining certain product-related regulatory certifications. As of December 31, 2022, the measurement period related to the contingent earn-out based on certain revenue targets ended and based on the actual revenue achieved during the measurement period the fair value of the contingent earn-out was determined to be zero as the minimum threshold for earning the earn-out was not met. As of June 30, 2024, the estimated fair value of the contingent consideration related to certain product-related regulatory certifications was estimated to be $1.5 million.

In August 2021, we entered into an agreement with one of our international distributors whereby that distributor would not compete with us in a specific territory for a three-year period that ends September 2024. The terms of the agreement included a contingent earn-out payment. The contingent earn-out payment could not exceed $6.0 million and was to be earned based on certain revenue targets over a twelve-month measurement period determined by the highest four consecutive quarters commencing over a two-year period starting on the closing date of the agreement and provided that the distributor is in compliance with its obligations under the agreement. As of December 31, 2023, the fair value of the contingent earn-out was determined to be $3.4 million and was paid out during the three months ended March 31, 2024.

    Our contingent earn-out liabilities are separately stated on our condensed consolidated balance sheets.

The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands):
Earn-out Liability
Accrued balance, January 1, 2024$5,491 
Change in fair value of earn-out (included in income from operations as a separate line item)(1)
295 
Accrued balance, March 31, 20245,786 
Change in fair value of earn-out (included in income from operations as a separate line item)(1)
(339)
Accrued balance, June 30, 2024$5,447 
Earn-out Liability
Accrued balance, January 1, 2023$25,572 
Change in fair value of earn-out (included in income from operations as a separate line item)(1)
(700)
Currency translation33 
Accrued balance, March 31, 202324,905 
Change in fair value of earn-out (included in income from operations as a separate line item)(1)
4,016 
Other11 
Currency translation1 
Accrued balance, June 30, 2023$28,933 
_______________________________
(1) Relates to the change in fair value of our Smiths Medical earn-out.
    
The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities related to Smiths Medical:

Smiths Medical Earn-out Liability
20

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Simulation Input
As of
June 30, 2024
As of
December 31, 2023
Volatility45.00 %47.00 %
Risk-Free Rate4.83 %4.18 %

Investments, Foreign Exchange Contracts and Interest Rate Contracts    

    As of June 30, 2024, we do not have any investment securities. Our investments historically consisted of corporate, government bonds and U.S. treasury securities. The fair value of our corporate and government bonds were estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs. The fair value of our U.S. treasury securities were based on quoted market prices in active markets and are included in the Level 1 fair value hierarchy.

    The fair value of our Level 2 foreign exchange contracts is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

The fair value of our Level 2 interest rate swaps is estimated using a pricing model that reflects the terms of the contracts, including the period to maturity, and relies on observable market inputs such as known notional value amounts and USD interest rate curves.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following Level 1, 2 and 3 inputs as defined above (in thousands):
 
Fair value measurements as of June 30, 2024
 Total carrying
value
Quoted prices
in active
markets for
identical
assets (level 1)
Significant
other
observable
inputs (level 2)
Significant
unobservable
inputs (level 3)
Assets:
Foreign exchange contracts:
Prepaid expenses and other current assets$3,623 $ $3,623 $ 
Other assets99  99  
Interest rate contracts:
Prepaid expenses and other current assets21,006  21,006  
Other assets9,584  9,584  
Total Assets$34,312 $ $34,312 $ 
Liabilities:
Contingent earn-out liability - ST$1,500 $ $ $1,500 
Contingent earn-out liability - LT3,947   $3,947 
Foreign exchange contracts:
Accrued liabilities1,473  1,473  
Other long-term liabilities314  314  
Total Liabilities$7,234 $ $1,787 $5,447 
21

ICU MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)


 
Fair value measurements as of December 31, 2023
 Total carrying
value
Quoted prices
in active
markets for
identical
assets (level 1)
Significant
other
observable
inputs (level 2)
Significant
unobservable
inputs (level 3)
Assets:
Available-for-sale debt securities:
Short-term corporate bonds$501 $ $501 $ 
Foreign exchange forwards:
Prepaid expenses and other current assets6,785  6,785  
Other assets673  673  
Interest rate contracts:
Prepaid expenses and other current assets23,065  23,065  
Other assets4,876  4,876  
Total Assets$35,900 $ $35,900 $ 
Liabilities:
Contingent earn-out liability - ST$4,879 $ $3,379 $1,500 
Contingent earn-out liability - LT3,991   3,991 
Foreign exchange contracts:
Accrued liabilities2,590  2,590 
Other long-term liabilities240  240 
Total Liabilities$11,700 $ $6,209 $5,491 
    
Note 9: Investment Securities

Investments in Available-for-sale Securities

    Our available-for-sale investment securities historically consisted of corporate bonds, government bonds and U.S. treasury securities and were considered “investment grade” and were carried at fair value.

As of June 30, 2024, we did not have any investment securities. As of December 31, 2023, the amortized cost, unrealized holding gains (losses) and fair value of our available-for-sale investment securities were as follows (in thousands):
As of December 31, 2023
Amortized CostUnrealized Holding
Gains (Losses)
Fair Value
Short-term corporate bonds$501 $